Healthcare & Life Sciences

NIH Delays Effective Date for Privacy Act Exemptions

The National Institutes of Health (NIH) has further delayed the effective date for a final rule concerning Privacy Act exemptions for its police records. The effective date is now May 5, 2025, extended from the previously scheduled March 21, 2025.

Uniformed Services University Board of Regents Meeting Notice

The Uniformed Services University of the Health Sciences (USUHS) has issued a notice for its Board of Regents quarterly meeting. The meeting will cover the approval of minutes, departmental reports, and degree conferrals, essential for maintaining accreditation and fulfilling the university's mission.

Proposed Rule to Remove Opioid Disorder Treatment Waiver Requirements

SAMHSA has issued a supplemental notice of proposed rulemaking to remove the waiver requirement for practitioners prescribing certain medications for opioid use disorder (OUD). This action follows amendments made by the Consolidated Appropriations Act, 2023, which eliminated the need for the waiver. Public comments are due by March 14, 2023.

Proposed Rule: Opioid Use Disorder Medication Regulations

The Department of Health and Human Services (HHS) has issued a Notice of Proposed Rulemaking to solicit public comment on proposed modifications to regulations concerning medications for opioid use disorder treatment. The comment period closes on February 14, 2023.

Proposed Federal Workplace Drug Testing Guidelines

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a proposed rule to update federal workplace drug testing guidelines. This consultation seeks public comment on the proposed changes to these guidelines.

SAMHSA Seeks Public Comments on Maternal Mental Health

The Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting public comments on questions related to maternal mental health. This consultation aims to gather input for the Task Force on Maternal Mental Health.

SAMHSA Proposed Rule: Mandatory Drug Testing Guidelines Using Oral Fluid

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued a proposed rule to establish mandatory guidelines for drug testing using oral fluid. This proposal aims to provide a standardized framework for federal agencies and contractors conducting such testing.

HHS Proposes Rescinding LGBTQI+ Children Placement Rule

The Administration for Children and Families (ACF) proposes to remove a final rule concerning designated placement requirements for LGBTQI+ children in foster care. This action follows a court decision vacating the rule, which the court found exceeded HHS's statutory authority. The public comment period for this proposed rescission ends April 6, 2026.

HHS Opioid Use Disorder Medications Correction

The Department of Health and Human Services (HHS) is issuing a correcting amendment to the final rule on Medications for the Treatment of Opioid Use Disorder. This document corrects outdated references within the regulation, with an effective date of February 23, 2026.

HHS Modifies Privacy Act System of Records

The Department of Health and Human Services (HHS) is modifying a Privacy Act system of records, System No. 09-90-0052, to include reporting on substance use disorder patient records. The comment period for these modifications ends on March 19, 2026.

HHS Drug Testing Panel Guidelines

The Department of Health and Human Services (HHS) has issued updated guidelines for authorized drug testing panels used in federal workplace drug testing programs. The current drug testing panels for urine and oral fluid, along with the required nomenclature for laboratory and Medical Review Officer Reports, remain in effect as of July 7, 2025, with minor edits to footnotes for clarity.

Osteopathic Family Physician Background Material

The FDA has posted background material related to Osteopathic Family Physicians. This notice provides informational content for stakeholders in the healthcare field.

FDA Complaint Document

The FDA has posted a complaint document related to FDA-2026-H-2392-0001. The document is available for download, though no specific details about the complaint's nature or the involved parties are provided in the metadata.

FDA Acknowledgment Letter to Athyna Pharma

The FDA's Center for Drug Evaluation and Research (CDER) has issued an acknowledgment letter to Athyna Pharma, LLC. This notice confirms receipt of a submission from the company.

FDA Approves Labeling for RLD, NDA N021411

The FDA has approved labeling for RLD (Reference Listed Drug) and NDA (New Drug Application) N021411. This notice indicates a regulatory action related to drug approval and labeling requirements.

FDA Complaint Document

The FDA has posted a complaint document related to FDA-2026-H-2191-0001. This document is open for public comment, with a deadline for submissions.

FDA Acknowledgment Letter to North Bay Productions

The FDA's Division of Management and Budget (DMB) issued an acknowledgment letter to North Bay Productions on March 13, 2026. This notice confirms receipt of a submission from the company.

FDA Natural Family Planning Curricula Background Material

The FDA has posted background material related to Natural Family Planning curricula. This notice provides informational resources for interested parties.

Draft Labeling for Atomoxetine HCL Solution

The FDA has posted draft labeling for Atomoxetine HCL Solution for public comment. This document outlines proposed changes to the drug's labeling, which will impact manufacturers and potentially healthcare providers.

Strattera Oral Solution SMPC Posting

The FDA has posted the Summary of Product Characteristics (SMPC) for Strattera oral solution on March 13, 2026. This posting provides updated information regarding the drug's characteristics and usage. It is intended for informational purposes for drug manufacturers and healthcare professionals.

FDA Proposes Pediatric Labeling Changes for ADHD Drugs

The FDA has issued a proposal to update the pediatric labeling for certain Attention Deficit Hyperactivity Disorder (ADHD) drugs. This consultation seeks public comment on the proposed changes to ensure accurate and up-to-date information for healthcare providers and patients regarding the use of these medications in children.

FDA Acknowledgment Letter to Irish Multimedia, LLC

The FDA has issued an acknowledgment letter to Irish Multimedia, LLC regarding a submission. The letter confirms receipt of the submission but provides no substantive details on its content or purpose.

FDA Complaint - Public Comment Period Closed

The FDA has posted a complaint document related to FDA-2026-H-2396-0001. The public comment period for this complaint has now closed. No specific details about the complaint's content or the agency's next steps are available in the provided information.

FDA Complaint Document

The FDA has posted a complaint document related to enforcement actions. The document, authored by CTP, is available for review. Further details on the specific allegations and parties involved are not provided in the initial posting.

FDA Complaint for Public Comment

The FDA has posted a complaint for public comment, with the comment period closing on March 13, 2026. The complaint was authored by the CTP and is available for download.

FDA Document Details

The Food and Drug Administration (FDA) has published details for a new document on regulations.gov. This notice provides access to the document and its associated information for interested parties. Further details regarding the document's content are available via the provided URL.

FDA Complaint Document

The FDA has posted a complaint document related to FDA-2026-H-2387-0001. The document is authored by CTP and is available for download. This indicates a new enforcement action or investigation has been initiated.

FDA Acknowledgment Letter to Special FX Rentals

The FDA's Center for Devices and Radiological Health (CDRH) has issued an acknowledgment letter to Special FX Rentals. This notice confirms receipt of documentation and does not indicate approval or disapproval of any submissions.

FDA Variance Approval Letter

The FDA has issued a variance approval letter to Richard Lathrop, authored by CDRH. The letter, which contains restricted personally identifiable information, has been redacted and is available for download.

FDA Document - Copyrighted Content

The FDA has posted a document containing copyrighted content, identified by the docket number FDA-2026-P-2640-0004. The content itself is restricted due to copyright. This notice serves to inform the public of the document's availability and its restricted nature.

FDA Document on Ovarian Cancer Risk Factors

The FDA has released a document concerning risk factors associated with ovarian cancer. This guidance is intended for manufacturers and healthcare providers involved in the pharmaceutical and medical device sectors.

FDA Natural Family Planning Review

The FDA has posted a review concerning Natural Family Planning methods. This document provides updated information and guidance related to these methods.

FDA Approves Labeling for RS, ANDA 202682

The U.S. Food and Drug Administration (FDA) has approved labeling for RS, as indicated by ANDA 202682. This approval was posted on March 13, 2026, and pertains to specific drug product labeling.

FDA Complaint Document Details

The US Food and Drug Administration (FDA) has posted details regarding a complaint document. The document is available for review, though no specific details about its content or the nature of the complaint are provided in the notice.

CDC Meeting Notice and Request for Comment on Immunization Practices

The CDC has issued a notice for a meeting of the Advisory Committee on Immunization Practices (ACIP) to be held on March 18-19, 2026. The notice also includes a request for written comments, which were due by March 12, 2026. The meeting agenda includes discussions on COVID-19 vaccine injuries and Long-COVID.

CDC Performance Measures Project Consultation

The Centers for Disease Control and Prevention (CDC) is seeking public comment on its Performance Measures Project. The comment period for this consultation closes on April 27th.

CDC Notice on Questionnaire Design and Evaluation Research

The Centers for Disease Control and Prevention (CDC) has issued a notice regarding research on questionnaire design and evaluation. This notice outlines the CDC's interest in advancing best practices for developing and assessing survey instruments used in public health research.

CDC Notice on Improving National Health and Nutrition Examination Survey Programs

The Centers for Disease Control and Prevention (CDC) has issued a notice regarding improvements to the National Health and Nutrition Examination Survey (NHANES) programs. This notice outlines updates and enhancements aimed at refining data collection and survey methodologies.

CDC Notice on Cognitive Testing with Comment Period

The CDC has issued a notice regarding cognitive testing, opening a comment period that closes on May 8. This consultation seeks input on proposed changes or new requirements related to cognitive assessment protocols.

Medicare/Medicaid CY 2026 Payment Policies Correction Notice

The Centers for Medicare & Medicaid Services (CMS) issued a correction notice for the CY 2026 Physician Fee Schedule final rule. This notice corrects typographical and technical errors in the original rule, which finalized payment policies for Medicare and Medicaid programs for calendar year 2026.

CMS Medicare Part C/D Reporting Requirements Notice Comment Period

The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information related to Medicare Part C and D reporting requirements. This notice provides a 60-day comment period for interested parties to submit feedback on the proposed information collection.

CMS Seeks Public Comment on Information Collection Activities

The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information from the public under the Paperwork Reduction Act. This notice provides an opportunity for interested parties to submit comments on the proposed information collection activities.

Medicare Advantage Deeming Authority Renewal for NCQA

The Centers for Medicare & Medicaid Services (CMS) is considering the renewal of the National Committee for Quality Assurance's (NCQA) Medicare Advantage deeming authority. This notice requests public comments on whether to approve NCQA's application to continue deeming Health Maintenance Organizations and Preferred Provider Organizations compliant with certain Medicare requirements.

Error Document Not Found

A document on regulations.gov returned a general error, indicating it could not be found. The error suggests the link may be outdated or incorrect, or the document has been removed. Users are advised to check the URL or return to the homepage.

Error Document Not Found

A general error occurred while processing a request on regulations.gov, indicating that the document or docket could not be found. Users are advised to check the URL or return to the homepage.

Regulations.gov Document Not Found Error

Regulations.gov is experiencing a technical error, preventing access to documents. Users are advised to check the URL, return to the homepage, or contact the Help Desk if the problem persists. The specific document referenced by the URL could not be found.

Error Page - Document Not Found

The regulations.gov website is displaying an error page indicating that a requested document could not be found. Users are advised that the link may be outdated or incorrect, and they should try returning to the homepage or contacting the Help Desk if the problem persists.

Public Health Service Rule Withdrawal

The Public Health Service has withdrawn a previously issued rule. This action removes the rule from the Code of Federal Regulations. Further details on the specific rule withdrawn are not provided in the document title.

ONDCP Senior Executive Service Performance Review Board Appointments

The Office of National Drug Control Policy (ONDCP) has announced the appointment of four individuals to its Senior Executive Service Performance Review Board. The notice, published on February 28, 2025, identifies the Chair and other members of this board.

Error Processing Request - Document Not Found

The US Federal Government website regulations.gov is experiencing an error, indicating that a requested document could not be found. Users are advised that the link may be outdated or incorrect, and they should try the URL again or contact the Help Desk if the problem persists.